Clozapine’s REMS Program on the Chopping Block at Upcoming FDA Meeting
MedPage Today) — Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That’s what a joint meeting of two FDA advisory committees will discuss on Tuesday. Risk management requirements for the atypical antipsychotic…
MedPage Today) — Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That’s what a joint meeting of two FDA advisory committees will discuss on Tuesday.
Risk management requirements for the atypical antipsychotic…
Read More
About Author
